The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland

被引：0
|
作者：
Thomas Ward
Tray Brown
Ruth D. Lewis
Melodi Kosaner Kliess
Antonio Ramirez de Arellano
Carol M. Quinn
机构：
[1] Health Economics and Outcomes Research Ltd.,Health Economics Group, College of Medicine and Health
[2] University of Exeter,Vifor Pharma Group
[3] HEOR,undefined
[4] Vifor Pharma Group,undefined
[5] Medical Department,undefined
来源：
PharmacoEconomics - Open | 2022年 / 6卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：757 / 771
页数：14
相关论文
共 50 条
  • [21] MANAGEMENT OF CHRONIC KIDNEY DISEASE IN PATIENTS WITH AND WITHOUT CONGESTIVE HEART FAILURE
    Faisa, Manthodi
    Burke, Peter
    Zhang, Wei
    Bowen, James
    Jurkovitz, Claudine
    Israni, Rubeen
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2012, 59 (04) : A34 - A34
  • [22] Practical guidance for the use of potassium binders in the management of hyperkalaemia in patients with heart failure and/or chronic kidney disease
    Campbell, Patricia
    McKeveney, Paul
    Donegan, Kay
    Ataliotis, Charlie
    Patton, Carol
    Mullan, Robert
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2021, 82 (04)
  • [23] DEVELOPMENT OF A MORTALITY RISK PREDICTION TOOL FOR PATIENTS WITH HEART FAILURE OR CHRONIC KIDNEY DISEASE AT RISK OF HYPERKALAEMIA
    Bennett, H.
    McEwan, P.
    Ayoubkhani, D.
    Evans, M.
    Qin, L.
    Kim, K.
    Palaka, E.
    VALUE IN HEALTH, 2017, 20 (09) : A682 - A682
  • [24] Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
    Esteban-Fernandez, Alberto
    Cortes, Carolina Ortiz
    Lopez-Fernandez, Silvia
    Mayoral, Alejandro Recio
    Camacho Jurado, Francisco Javier
    Otero, Ines Gomez
    Molina, Maria
    Bonet, Luis Almenar
    Lopez-Vilella, Raquel
    ESC HEART FAILURE, 2022, 9 (05): : 3071 - 3078
  • [25] Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
    Mark Bounthavong
    Javed Butler
    Chantal M. Dolan
    Jeffrey D. Dunn
    Kathryn A. Fisher
    Nina Oestreicher
    Bertram Pitt
    Paul J. Hauptman
    David L. Veenstra
    PharmacoEconomics, 2019, 37 : 1071 - 1071
  • [26] ASSESSING THE COST-EFFECTIVENESS OF PATIROMER PLUS SPIRONOLACTONE THERAPY IN HEART FAILURE PATIENTS WITH HYPERKALEMIA
    Bounthavong, M.
    Butler, J.
    Dolan, C. M.
    Dunn, J. D.
    Fisher, K. A.
    Oestreicher, N.
    Pitt, B.
    Hauptman, P. J.
    Veenstra, D. L.
    VALUE IN HEALTH, 2017, 20 (05) : A271 - A271
  • [27] Impact of treatment of hyperkalaemia on quality of life: design of a prospective observational cohort study of long-term management of hyperkalaemia in patients with chronic kidney disease or chronic heart failure in Japan
    Shibagaki, Yugo
    Yamazaki, Hajime
    Wakita, Takafumi
    Ware, John E.
    Wang, Jui
    Onishi, Yoshihiro
    Yajima, Toshitaka
    Sada, Ken-Ei
    Yamamoto, Yosuke
    Fukuhara, Shunichi
    BMJ OPEN, 2023, 13 (12):
  • [28] Cost Effectiveness of Eplerenone in Patients with Chronic Heart Failure
    Zanfina Ademi
    Kumar Pasupathi
    Henry Krum
    Danny Liew
    American Journal of Cardiovascular Drugs, 2014, 14 : 209 - 216
  • [29] Cost Effectiveness of Eplerenone in Patients with Chronic Heart Failure
    Ademi, Zanfina
    Pasupathi, Kumar
    Krum, Henry
    Liew, Danny
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (03) : 209 - 216
  • [30] Diabetes mellitus has the prognostic impact in chronic heart failure patients with chronic kidney disease but not without chronic kidney disease
    Fukunami, MMasatake
    Yamada, T.
    Morita, T.
    Furukawa, Y.
    Tamaki, S.
    Iwasaki, Y.
    Kawasaki, M.
    Kikuchi, A.
    Kondoh, T.
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 322 - 322
12345